Press coverage about Vistagen Therapeutics (NASDAQ:VTGN) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vistagen Therapeutics earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.1510836371046 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
Get Vistagen Therapeutics alerts:
Investor’s Alert (Earnings Per Share) VistaGen Therapeutics Inc (NASDAQ: VTGN) (stocksmarketcap.com) Stock Technical’s & Performances to Explore VistaGen Therapeutics Inc (NASDAQ: VTGN) (stockspen.com) US STOCKS ON THE MOVE-Media and telecom stocks, H & R Block, TAL Education (nasdaq.com) Tracking the HMA Level on These Shares: VistaGen Therapeutics, Inc. (:VTGN): HMA Reading 1.4214792 (stocknewscaller.com) Keep Your Eyes on Hot Stock of Yesterday VistaGen Therapeutics, Inc. (VTGN) (stockmarketstop.com)
Vistagen Therapeutics traded down $0.02, reaching $1.46, on Tuesday, according to MarketBeat Ratings. The company’s stock had a trading volume of 2,930 shares, compared to its average volume of 2,201,613. The stock has a market cap of $34.35 million, a P/E ratio of -0.95 and a beta of 0.29. Vistagen Therapeutics has a 52 week low of $0.69 and a 52 week high of $2.65.
A number of research analysts have recently commented on the stock. Oppenheimer initiated coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set a “buy” rating and a $6.00 price objective for the company. UBS Group initiated coverage on shares of Vistagen Therapeutics in a research note on Thursday, May 24th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, Zacks Investment Research reissued a “buy” rating and issued a $1.00 target price on shares of Vistagen Therapeutics in a research note on Saturday, April 7th.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.